Navigation Links
Atherosclerosis: Specific microRNAs promote inflammation
Date:3/22/2013

Atherosclerosis, an inflammatory reaction, is at the root of the most common forms of cardiovascular disease. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have now identified a microRNA that plays a prominent role in the process, and offers a promising target for new therapies.

Atherosclerosis otherwise known as hardening of the arteries is a prevalent cause of death in modern societies. The condition arises from the build-up of localized fatty deposits called plaques in the arteries. Macrophages, the phagocytic cells of the immune system, migrate to these sites, inducing chronic inflammation which exacerbates the accumulation of the atherosclerotic lesions. These can lead to obstruction of major vessels, causing heart attack and stroke. A team of medical researchers led by LMU's Professor Andreas Schober has now identified a microRNA (miRNA) that helps initiate the inflammatory process.

miRNAs are short segments of RNA derived from longer precursors transcribed from defined stretches of the genomic DNA. They act as versatile regulators of gene expression in cells, and also control the function of macrophages, in which patterns of gene activity must respond rapidly to changes in the extracellular environment. "However, the miRNAs that control the inflammation process during the various stages of atherosclerosis had not been identified up to now," says Schober.

In an earlier study, Schober and his team had shown that the microRNA miR-155 is a prominent member of the miRNA population in macrophages. The molecule prevents the synthesis of a protein that inhibits the inflammatory reaction, and thus promotes the progression of atherosclerosis. However, miR-155 does not serve as the initiator of inflammation. Schober and his colleagues have now looked at the patterns of microRNA expression in atherosclerotic lesions in the mouse, and noted that levels of a different miRNA, called miR-342-5p, increase in very early plaques.

New therapeutic approaches

"The newly identified miR-342-5p is actually expressed constituently in macrophages, but it is activated by pro-inflammatory signals. This activation process then induces production of miR-155," Schober explains. The results of the new study thus make miR-342-5p an interesting target for new therapeutic agents. Indeed, in their animal model, the researchers have been able to demonstrate that inhibition of the action of miR-342-5p by means of a specific antagonist retards the progression of atherosclerosis.

"Atherosclerosis in humans should also be susceptible to treatment with inhibitors of microRNAs," Schober suggests. "Synthetic inhibitors are available for each and every microRNA, and could be used for therapeutic purposes as soon as their efficacy and safety has been demonstrated in clinical tests." Hence the researchers now plan to collaborate with biotechnology companies on the development of their own specific microRNA inhibitor for future clinical use.


'/>"/>

Contact: Luise Dirscherl
dirscherl@lmu.de
49-892-180-2706
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related medicine news :

1. Brain waves challenge area-specific view of brain activity
2. Researchers propose a novel prognostic model for disease-specific survival in BCa patients
3. Stroke risk in elderly treated with antipsychotics is newly linked to specific drug actions
4. US Drug Watchdog Now Urges Personal Injury Law Firms To Help Them Help Injured Individuals Of A Transvaginal Mesh Failure With A State Specific Approach-The Worst Victims
5. US Drug Watchdog Now Urges Top Personal Injury Trial Lawyers To Join Their State Specific Effort To Help Victims Of A Severe Transvaginal Mesh Failure To Get Compensation
6. US Drug Watchdog Now Invites Top Personal Injury Law Firms To Join Them In A State Specific Effort To Identify And Help Victims Of A Severe Transvaginal Mesh Failure
7. US Drug Watchdog Now Urges AV Rated Law Firms To Help Them Help More Victims Of A Severe Transvaginal Mesh Failure With A State Specific Approach
8. US Drug Watchdog Now Urges Trial Law Firms To Join Them In Their Effort To Help Severely Injured Victims Of A Transvaginal Mesh Failure-With A State Specific Approach
9. Prostate-specific antigen screening: Values and techniques shape decisions
10. Specific warning signs of complications in colorectal surgical patients released
11. US Drug Watchdog Now Urges All US Recipients of All Metal Hip Implants to Get a Blood Test For Cobalt-Chromium Levels and They Offer Specific Law Firms For Failure Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The Texas ... in recently to the labor and delivery team at Women’s Hospital at Renaissance in ... who give birth at the hospital and decide to donate. , “Women’s Hospital ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... , ... Intellitec Solutions announced the publication of a case ... GP solution that integrates to their PointClickCare EHR software package. With the guidance ... Grove now has the capability to achieve its goal for a comprehensive EHR ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s ... is the premier online modeling resource for fluorescence microscopists and optical system designers, ... during last 5 years spanning the globe, SearchLight has become a tremendously popular ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: